Drug Profile
GBT 016
Alternative Names: GBT016Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Genbiotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 28 Mar 2023 Preclinical development for Osteoarthritis is ongoing in France (Genbiotech pipeline, March 2023)
- 05 Feb 2014 Preclinical trials in Osteoarthritis in France (unspecified route)